MedPath

Dextran

Generic Name
Dextran
Brand Names
Bion Tears, Colirio Ocusan, Genteal Tears, Genteal Tears Mild, Tears Naturale, Tears Renewed
Drug Type
Small Molecule
CAS Number
9004-54-0
Background

Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links. The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units. Many bacteria, like Leuconostoc, can synthesize dextran from sucrose, and this activity is used commercially to obtain dextran.

Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran (average mol. wt. 40,000) in 5% Dextrose Injection or 0.9% Sodium Chloride Injection. It is administered by intravenous infusion.

Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. It is produced from certain bacteria that with α-1,6 glycosidic linkages between glucose molecules and α-1,3 linkages between branches. When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular aneurysm.

Indication

Dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration. It is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15% of the blood mass, if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection. Dextran is also used for the prevention of profound postoperative venous thrombosis.

Dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritations.

Associated Conditions
Blood Circulation Disorder, Capillary disorder, Dry Eyes, Ocular Irritation, Pulmonary Embolism, Pulmonary Embolism caused by procedures associated with a high incidence of thromboembolic complications, Shock, Thrombosis, Venous Thrombosis (Disorder), Venous Thrombosis caused by procedures associated with a high incidence of thromboembolic complications
Associated Therapies
Plasma Volume Replacement, Priming fluid in pump oxygenators therapy

Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG

First Posted Date
2013-11-07
Last Posted Date
2013-11-07
Lead Sponsor
University of Campinas, Brazil
Target Recruit Count
69
Registration Number
NCT01978015
Locations
🇧🇷

Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

First Posted Date
2012-11-26
Last Posted Date
2014-01-14
Lead Sponsor
Allergan
Target Recruit Count
157
Registration Number
NCT01732757

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

First Posted Date
2011-11-11
Last Posted Date
2013-02-21
Lead Sponsor
Allergan
Target Recruit Count
127
Registration Number
NCT01470118

Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis

Phase 4
Terminated
Conditions
Spontaneous Bacterial Peritonitis
Interventions
Biological: human albumin
First Posted Date
2007-12-11
Last Posted Date
2014-12-03
Lead Sponsor
University of Virginia
Target Recruit Count
8
Registration Number
NCT00570960
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Phase 2
Completed
Conditions
Non-Myeloid Malignancies
Anemia
Interventions
First Posted Date
2006-11-20
Last Posted Date
2014-01-29
Lead Sponsor
Amgen
Target Recruit Count
243
Registration Number
NCT00401544

Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
6
Registration Number
NCT00000690
Locations
🇺🇸

Johns Hopkins Hosp, Baltimore, Maryland, United States

A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
60
Registration Number
NCT00001009
Locations
🇺🇸

Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States

🇺🇸

Univ of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

UCLA CARE Ctr, Los Angeles, California, United States

and more 5 locations

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
10
Registration Number
NCT00000684
Locations
🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath